On Friday, Newell Rubbermaid Inc. (NYSE:NWL)’s shares declined -0.35% to $40.02.
Newell Rubbermaid Inc. (NWL) declared that President and Chief Executive Officer Michael Polk will present at the Deutsche Bank Global Consumer Conference in Paris, France. The presentation will start at 2:30 a.m. EDT (8:30 a.m. CEST) on Tuesday, June 9, 2015.
Newell Rubbermaid Inc. manufactures and markets consumer and commercial products worldwide. It operates through five segments: Writing, Home Solutions, Tools, Commercial Products, and Baby & Parenting. The Writing segment offers writing instruments, such as markers and highlighters, pens, and pencils; art products; fine writing instruments; and labeling solutions under the Sharpie, Paper Mate, Expo, Parker, Waterman, and Dymo Office brand names.
Heron Therapeutics Inc (NASDAQ:HRTX)’s shares dropped -0.46% to $26.20.
Heron Therapeutics Inc (HRTX) declared positive, top-line results from its accomplished Phase 3 MAGIC study. MAGIC evaluated the efficacy and safety of the Company’s 5-HT3 receptor antagonist product candidate SUSTOL® (granisetron injection, extended release) as part of a three-drug regimen with the intravenous (IV) neurokinin-1 (NK1) receptor antagonist fosaprepitant and the IV corticosteroid dexamethasone for the prevention of delayed-onset chemotherapy-induced nausea and vomiting (CINV) following administration of highly emetogenic chemotherapy (HEC) agents.
NSHOA Cancer Center had a major impact in the MAGIC study. Jeffrey Vacirca, M.D., was chosen to be Principal Investigator for the study for the entire country and NSHOA Cancer Center was one of the top enrollers in the United States. The study was conducted entirely in the U.S. and enrolled over 900 patients undergoing HEC treatment for various tumor types.
The study’s primary endpoint was achieved. The percentage of patients who achieved a Complete Response was significantly higher in the SUSTOL group than the comparator group.
Heron Therapeutics, Inc. is a biotechnology company. The Company is using its proprietary technology to develop products to address unmet medical needs. Its Biochronomer polymer-based drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by extending the duration of action of known active ingredients. Heron’s product candidate, SUSTOL (granisetron injection, extended release), is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting.
At the end of Friday’s trade, Voya Financial Inc (NYSE:VOYA)‘s shares surged 0.28% to $46.58.
Voya Financial Inc (VOYA) declared that the company has been named to the 2015 Fortune 500 list. Voya Financial’s appearance on the 2015 Fortune 500 at No. 268 marks the company’s entrance to the list, which is Fortune magazine’s annual ranking of America’s largest companies by revenue. Voya Financial is the second-highest ranked new entrant to the Fortune 500.
Voya Financial also declared that it has been recognized as one of the Top Green Companies in the U.S. 2015 by Newsweek magazine, ranking as No. 78 of the 500 U.S. companies to earn the designation for corporate sustainability and environmental impact.
Inherent to its culture and brand, Voya Financial is committed to conducting business in a way that is socially, environmentally, economically, and ethically responsible. In March, Voya was recognized by the Ethisphere Institute as one of the World’s Most Ethical Companies for the second successive year.
Voya Financial, Inc. operates as a retirement, investment, and insurance company in the United States. The company has five segments: Retirement, Annuities, Investment Administration, Individual Life, and Employee Benefits. The Retirement segment offers tax-deferred employer-sponsored retirement savings plans and administrative services in corporate, education, healthcare, and government markets; and rollover individual retirement accounts and other retail financial products, in addition to financial advisory services to individual customers.
TiVo Inc. (NASDAQ:TIVO), ended its Friday’s trading session with 0.57% gain, and closed at $10.64.
TiVo Inc. (TIVO) declared that its CubiTV hybrid middleware has been selected by Global Satellite (GSat) for delivery of digital video broadcast via satellite in the Philippines. CubiTV will be deployed on set-top boxes (STBs) manufactured by Intek Digital of South Korea and used to provide direct-to-home satellite TV services to subscribers across the Philippines. Initial capabilities enabled by the Intek/Cubiware STBs comprise high definition digital video and PVR recording. The inclusion of CubiTV provides an upgrade path that will enable later deployment of interactive services and additional improved capabilities.
GSat provides international entertainment and information in multiple Asian markets, counting not only the Philippines but also other parts of South Asia. With an emphasis on superior coverage, quality programming, and content security, GSat carries both locally produced and international content, counting news, multi-cultural programs, distance education, business and economic analysis, governmental proceedings, and other documentary productions. GSat’s services reach remote areas that are often not served by terrestrial broadcast or cable.
TiVo Inc. provides television software services and cloud-based software-as-a-service solutions that enable to view video content through various screens. It offers whole-home solutions that comprise 4-Tuner and 6-Tuner digital video recorders (DVRs)/gateways, non-DVR IP set-top boxes (STBs), and software to enable streaming to application on third-party devices, such as iOS and Android mobile phones and tablets through features, such as What to Watch Now, OnePass, integrated search, access to broadband video content, and TiVo online/mobile scheduling.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
